Please use this identifier to cite or link to this item: https://doi.org/10.3389/fonc.2013.00093
DC FieldValue
dc.titleDissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration
dc.contributor.authorLoh, A.H
dc.contributor.authorBrennan, R.C
dc.contributor.authorLang, W.H
dc.contributor.authorHickey, R.J
dc.contributor.authorMalkas, L.H
dc.contributor.authorSandoval, J.A
dc.date.accessioned2020-11-10T00:28:16Z
dc.date.available2020-11-10T00:28:16Z
dc.date.issued2013
dc.identifier.citationLoh, A.H, Brennan, R.C, Lang, W.H, Hickey, R.J, Malkas, L.H, Sandoval, J.A (2013). Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration. Frontiers in Oncology 43558 : Article 00093. ScholarBank@NUS Repository. https://doi.org/10.3389/fonc.2013.00093
dc.identifier.issn2234943X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/183186
dc.description.abstractChildren with solid tumors represent a unique population. Recent improvements in pediatric solid tumor survival rates have been confined to low- and moderate-risk cancers, whereas minimal to no notable improvement in survival have been observed in high-risk and advanced-stage childhood tumors. Treatments for patients with advanced disease are rarely curative, and responses to therapy are often followed by relapse, which highlights the large unmet need for novel therapies. Recent advances in cancer treatment have focused on personalized therapy, whereby patients are treated with agents that best target the molecular drivers of their disease. Thus, a better understanding of the pathways that drive cancer or drug resistance is of critical importance. One such example is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, which is activated in many solid cancer patients and represents a target for therapy. PI3K/Akt/mTOR pathway activation has also been observed in tumors resistant to agents targeting upstream receptor tyrosine kinases (RTKs). Agents that target this pathway have the potential to shut down survival pathways, and are being explored both in the setting of pathway-activating mutations and for their ability to restore sensitivity to upstream signaling targeted agents. Here, we examine the role of the PI3K/Akt/mTOR pathway in pediatric solid tumors, review the novel agents being explored to target this pathway, and explore the potential role of the inhibition of this pathway in the clinical development of these agents in children. © 2013 Loh, Brennan, Lang, Hickey, Malkas and Sandoval.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subject2 morpholino 8 phenylchromone
dc.subject8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one
dc.subject8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one
dc.subjectalendronic acid
dc.subjectbuparlisib
dc.subjectcixutumumab
dc.subjectcyclophosphamide
dc.subjectdactolisib
dc.subjectdalotuzumab
dc.subjectdoxorubicin
dc.subjectenzastaurin
dc.subjectetoposide
dc.subjecteverolimus
dc.subjectirinotecan
dc.subjectlomustine
dc.subjectmammalian target of rapamycin
dc.subjectperifosine
dc.subjectphosphatidylinositol 3 kinase
dc.subjectphosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase
dc.subjectprotein kinase B
dc.subjectprotein tyrosine kinase
dc.subjectrapamycin
dc.subjectridaforolimus
dc.subjecttemozolomide
dc.subjecttemsirolimus
dc.subjecttopotecan
dc.subjecttranscription factor FKHR
dc.subjecttranscription factor FOXO
dc.subjectunclassified drug
dc.subjectunindexed drug
dc.subjectvinblastine
dc.subjectwortmannin
dc.subjectapoptosis
dc.subjectcancer inhibition
dc.subjectcancer recurrence
dc.subjectcancer survival
dc.subjectcell proliferation
dc.subjectchild
dc.subjectchildhood cancer
dc.subjectdrug dose escalation
dc.subjectdrug efficacy
dc.subjectdrug tolerability
dc.subjectenzyme inhibition
dc.subjectEwing sarcoma
dc.subjectfebrile neutropenia
dc.subjectgene mutation
dc.subjecthematologic disease
dc.subjecthuman
dc.subjectmucosa inflammation
dc.subjectneuroblastoma
dc.subjectnonhuman
dc.subjectosteosarcoma
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectphase 3 clinical trial (topic)
dc.subjectprotein expression
dc.subjectrandomized controlled trial (topic)
dc.subjectreview
dc.subjectrhabdomyosarcoma
dc.subjectsignal transduction
dc.subjectsingle drug dose
dc.subjectsolid tumor
dc.subjectthrombocytopenia
dc.typeReview
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.3389/fonc.2013.00093
dc.description.sourcetitleFrontiers in Oncology
dc.description.volume43558
dc.description.pageArticle 00093
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fonc_2013_00093.pdf537.3 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

11
checked on Dec 1, 2022

Page view(s)

163
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons